PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Core Viewpoint - Wall Street anticipates a year-over-year increase in earnings for PTC Therapeutics despite lower revenues, with actual results being crucial for stock price movement [1][2]. Earnings Expectations - The earnings report is set to be released on November 4, with expectations of a quarterly loss of $1.19 per share, reflecting a year-over-year change of +14.4%. Revenues are projected at $175.6 million, down 10.8% from the previous year [3][2]. Estimate Revisions - The consensus EPS estimate has been revised 12.37% higher in the last 30 days, indicating a collective reassessment by analysts [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model shows a positive Earnings ESP of +5.75% for PTC Therapeutics, suggesting a likelihood of beating the consensus EPS estimate [12]. Historical Performance - PTC Therapeutics has a history of beating consensus EPS estimates, having done so in the last four quarters, including a +22.43% surprise in the last reported quarter [13][14]. Additional Considerations - While an earnings beat may influence stock movement, other factors can also play a significant role in determining stock performance post-earnings release [15][17].